Treatment of hairy cell leukemia with recombinant alpha-interferon

Quesada, Jorge R.; Hersh, E.; Manning, John T.; Reuben, James M.; Keating, MJ; Schnipper, Edward F.; Itri, Loretta M.; Ju, Gutterman

doi:10.1182/blood.v68.2.493.493

Cited by 226 publications

(53 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nine (30%) CR and 17 (56%) PR were confirmed by bone marrow core biopsies. All patients' peripheral blood hematologic indices either improved or normalized [33]. A multicenter phase II study of 64 patients published in 1986 confirmed the drug's efficacy in hairy cell leukemia [34].…”

Section: Hairy Cell Leukemiamentioning

confidence: 79%

Interferon in Oncological Practice: Review of Interferon Biology, Clinical Applications, and Toxicities

2001

View full text Add to dashboard Cite

For the past 40 years, various forms of interferon (IFN) have been evaluated as therapy in a number of malignant and non-malignant diseases. With the advent of gene cloning, large quantities of pure IFN became available for clinical study. This paper reviews the biology, pharmacology, and clinical applications of IFN formulations most commonly used in oncology. It then reviews the most common side effects seen in patients treated with IFN, and makes recommendations for the management of IFN-induced toxicity.The major oncological indications for IFN include melanoma, renal cell carcinoma, AIDS-related Kaposi's sarcoma, follicular lymphoma, hairy cell leukemia, and chronic myelogenous leukemia. Unfortunately, IFN therapy is associated with significant toxicity, which can be divided into constitutional, neuropsychiatric, hematologic, and hepatic effects. These toxicities have a major impact on the patient's quality of life, and on the physician's ability to optimally treat the patient. Careful attention to all aspects of patient care can result in improved tolerability of this difficult but promising therapy. Conclusion: a better understanding of IFN biology, indications, side effect profiles, and toxicity management will aid in optimizing its use in the treatment of patients with cancer. The Oncologist 2001;6:34-55

show abstract

Section: Hairy Cell Leukemiamentioning

confidence: 79%

Interferon in Oncological Practice: Review of Interferon Biology, Clinical Applications, and Toxicities

2001

View full text Add to dashboard Cite

show abstract

“…However, glyco-peptides containing L28N were not detected by mass spectrometry, suggesting that the site may have remained unmodified. According to the recent cryo-EM structure of oligosaccharyltransferase (OST) [34][35][36], which catalyzes the initial transfer of glycan from the [37][38][39]. IFNβ is a well-known treatment for multiple sclerosis, with a number of different versions available (Rebif -IFNβ 1a, liquid form, Avonex -IFNβ 1a, lyophilized, Cinnovex -IFNβ 1a, biogeneric, Betaseron -IFNβ 1b, Plegridy -PEGylated IFNβ 1a) [40][41][42][43].…”

Section: Discussionmentioning

confidence: 99%

Structure-based glycoengineering of interferon lambda 4 enhances its productivity and anti-viral potency

et al. 2020

View full text Add to dashboard Cite

Interferon lambda 4 (IFNλ4) has been recently known and studied for its role in hepatitis C virus (HCV) infection, but its clinical potential is significantly hampered due to its poor expression in vitro. Our study reports the successful production of IFNλ4 from a mammalian cell line through a glycoengineering and structure-based approach. We introduced de novo N-glycosylation of IFNλ4, guided by structural analysis, and produced IFNλ4 variants in Expi293F that displayed improved expression and potency. To preserve the structure and functionality of IFNλ4, the model structure of the IFNλ4 signaling complex was analyzed and the N-glycosylation candidate sites were selected. The receptor binding activity of engineered IFNλ4 variants and their receptormediated signaling pathway were similar to the E. coli version of IFNλ4 (eIFNλ4), while the antiviral activity and induction levels of interferon-stimulated gene (ISG) were all more robust in our variants. Our engineered IFNλ4 variants may be further developed for clinical applications and utilized in basic research to decipher the immunological roles of IFNλ4. Previously, the transient expression of wild-type IFNλ4 in mammalian cells failed to produce significant amounts of recombinant

show abstract

“…Clinical relapses have been observed in 33% to 48% of patients with HCL after interferon treatment, and the median time to disease progression after cessation of interferon therapy has ranged from 6 to 25 months. 44,50,56,57 The disease-free survival rate at 2 years has ranged from 25% to 60% in different ~e r i e s .~" ,~~ Patients with a neutrophil alkaline phosphatase (NAP) level of less than 30 have had a median failure-free survival time of 30.4 months, compared with 12.4 months in patients with greater than 30% hairy cells in the bone marrow and a NAP of 30 or more.56 A median failure-free survival time of 23.5 months has been observed in patients with a NAP of 30 or more and 30% or fewer hairy cells. Patients who express the CD5 antigen have been found to respond poorly to i n t e r f e r~n .~~…”

Section: Interferonsmentioning

confidence: 99%

Advances in therapy for hairy cell leukemia

Jaiyesimi

Kantarjian

Estey

1993

Cancer

View full text Add to dashboard Cite

Background. Hairy cell leukemia (HCL) is a chronic B‐cell malignancy, typically seen in middle‐aged men, characterized by pancytopenia, splenomegaly, immunologic abnormalities, and morphologically typical neoplastic mononuclear cells in the blood, bone marrow, liver, spleen, and other tissues. Diagnosis is confirmed by demonstration of hairy cells in biopsy specimens from the bone marrow or spleen or in peripheral blood. The natural history of this lymphoproliferative disorder varies. Patients may die early during the initial phase of therapy; others may require no therapy; and for some, splenectomy alone, without further treatment, may suffice for many years. Recently, the nucleosides pentostatin (2′‐deoxycoformycin) (DCF) and 2′‐chlorodeoxyadenosine (2‐CdA) have been shown to produce greater numbers of durable complete remissions with curative potential in patients with HCL. The treatment options, with emphasis on major therapeutic advances with alpha‐interferon, DCF, and 2‐CdA, are reviewed in this article. Methods. Studies on HCL published from 1958 to 1992 were reviewed using the Cancerline and Medline retrieval systems and other bibliographies. Results. Management of HCL has changed in the last decade as a result of three new effective agents: alpha‐interferon, DCF, and 2‐CdA. DCF has produced an overall response rate of 86% and a complete remission rate of 62%. 2‐CdA has yielded an overall response rate of 95% and a complete remission rate of 82%. Alpha‐interferon has given an overall response rate of 82% and a complete remission rate of 8%. Other agents with limited activities include chlorambucil, cyclophosphamide, cytarabine, vincristine, doxorubicin, and zorubicin hydrochloride. The effects of lithium carbonate, immunotherapy, splenic irradiation, androgens, and leukaphoresis are minimal and transient. Conclusions. Modern management of HCL with 2‐CdA and DCF is now potentially curative rather than palliative in some patients; however, the optimal therapeutic approach remains uncertain. Alpha‐interferon has been approved by the Food and Drug Administration as the first‐line drug therapy, followed by DCF in non‐responding patients. 2‐CdA remains an experimental therapy, but its higher response rate and ease of administration may make it the first‐line treatment of choice. Additional research into the biology of HCL and further clinical trials are needed to determine the optimal treatment strategy for this disorder. Therefore, the best therapeutic approach at the current time is to include patients with HCL in ongoing clinical trials.Cancer 1993; 72:5–16.

show abstract

Treatment of hairy cell leukemia with recombinant alpha-interferon

Cited by 226 publications

References 8 publications

Interferon in Oncological Practice: Review of Interferon Biology, Clinical Applications, and Toxicities

Interferon in Oncological Practice: Review of Interferon Biology, Clinical Applications, and Toxicities

Structure-based glycoengineering of interferon lambda 4 enhances its productivity and anti-viral potency

Advances in therapy for hairy cell leukemia

Contact Info

Product

Resources

About